Announcement PDF ASX Announcement Results of Annual General Meeting 27 November 2023 – Race Oncology Limited (“Race”) advises that its Annual General Meeting of Shareholders was held today at 12.00 pm AEDT. The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange. All resolutions were passed on a poll. Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached to this announcement. -ENDSAbout Race Oncology (ASX: RAC) Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Race’s lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anti-cancer activity in solid tumours. Race is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia. Race is investigating the effect of bisantrene on the m6A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesityassociated protein). Dysregulation of the m6A RNA pathway has been described in numerous peer reviewed studies to be a driver of a diverse range of cancers. Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world. Learn more at www.raceoncology.com. If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub https://announcements.raceoncology.com Race encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at www.automicgroup.com.au. Release authorised by: Media contact: The Race Oncology Board of Directors info@raceoncology.com Jane Lowe +61 411 117 774 jane.lowe@irdepartment.com.au Race Oncology Ltd ABN 61 149 318 749 L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • raceoncology.com Disclosure of Proxy Votes Automic GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@automic.com.au ABN 27 152 260 814 Race Oncology Limited Annual General Meeting Monday, 27 November 2023 In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting. Poll Results (if applicable) Proxy Votes Resolution Decided by Show of Hands (S) or Poll (P) Total Number of Proxy Votes exercisable by proxies validly appointed 1 ADOPTION OF REMUNERATION REPORT P 28,847,882 2 ELECTION OF DIRECTOR – DR PETER SMITH P 45,951,409 3 RE-ELECTION OF DIRECTOR – PHILLIP LYNCH P 45,507,260 4 ISSUE OF DIRECTOR OPTIONS TO DIRECTOR – MARY HARNEY P 28,871,900 5 ISSUE OF DIRECTOR OPTIONS TO DIRECTOR – PETER SMITH P 29,136,850 FOR AGAINST 24,100,836 2,036,295 83.54% 7.06% 43,233,152 107,506 94.08% 0.23% 41,097,860 1,800,434 90.31% 3.96% 23,234,858 2,913,112 80.48% 10.09% 25,696,461 829,459 88.19% 2.85% ABSTAIN 366,210 14,127 458,276 342,192 77,242 PROXY'S DISCRETION FOR AGAINST 2,710,751 30,573,220 2,154,295 9.40% 93.42% 6.58% 2,610,751 49,746,936 107,506 5.68% 99.78% 0.22% 2,608,966 46,706,790 2,703,503 5.73% 94.53% 5.47% 2,723,930 28,836,193 3,702,465 9.43% 88.62% 11.38% 2,610,930 32,067,024 949,459 8.96% 97.12% 2.88% Results ABSTAIN OUTCOME 366,210 - 14,127 Passed 458,276 Passed 555,067 Passed 77,242 Passed